Radiographic characteristics and poor prognostic factors of interstitial lung disease (ILD) in nivolumab-treated patients with non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Sasaki, S. [1 ]
Oikado, K. [2 ]
Saito, Y. [3 ]
Tominaga, J. [4 ]
Sata, M. [5 ]
Sakai, F. [6 ]
Kato, T. [7 ]
Iwasawa, T. [8 ]
Kenmotsu, H. [9 ]
Kusumoto, M. [10 ]
Baba, T. [11 ]
Endo, M. [12 ]
Fujiwara, Y. [13 ]
Sugiura, H. [14 ]
Yanagawa, N. [15 ]
Ito, Y. [16 ]
Sakamoto, T. [16 ]
Ohe, Y. [17 ]
Kuwano, K. [18 ]
机构：
[1] Juntendo Univ, Urayasu Hosp, Resp Med, Chiba, Japan
[2] Canc Inst Hosp, Dept Diagnost Imaging, Tokyo, Japan
[3] Nippon Med Coll Hosp, Dept Pulm Med & Oncol, Tokyo, Japan
[4] Tohoku Univ, Sch Med, Dept Diagnost Radiol, Sendai, Miyagi, Japan
[5] Jichi Med Univ Hosp, Div Pulm Med, Shimotsuke, Tochigi, Japan
[6] Saitama Med Univ, Int Med Ctr, Dept Diagnost Radiol, Hidaka, Japan
[7] Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan
[8] Kanagawa Cardiovasc & Resp Ctr, Dept Radiol, Yokohama, Kanagawa, Japan
[9] Shizuoka Canc Ctr, Div Thorac Oncol, Nagaizumi, Shizuoka, Japan
[10] Natl Canc Ctr, Dept Diagnost Radiol, Tokyo, Japan
[11] Kanagawa Cardiovasc & Resp Ctr, Dept Resp Med, Yokohama, Kanagawa, Japan
[12] Shizuoka Canc Ctr, Div Diagnost Radiol, Nagaizumi, Shizuoka, Japan
[13] Mitsui Mem Hosp, Dept Resp Med, Tokyo, Japan
[14] Keio Univ, Sch Med, Dept Diagnost Radiol, Tokyo, Japan
[15] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Radiol, Tokyo, Japan
[16] Ono Pharmaceut Co Ltd, Pharmacovigilance Div, Osaka, Japan
[17] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[18] Jikei Univ, Sch Med, Dept Internal Med, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1299P
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series
    Kanazu, Masaki
    Edahiro, Ryuya
    Krebe, Hiroyuki
    Nishida, Kohei
    Ishijima, Mikako
    Uenami, Takeshi
    Akazawa, Yuki
    Yano, Yukihiro
    Yamaguchi, Toshihiko
    Mori, Masahide
    THORACIC CANCER, 2018, 9 (12) : 1782 - 1787
  • [32] Hypoalbuminemia as a risk factor of interstitial lung disease (ILD) during gefitinib treatment in patients with non-small cell lung cancer (NSCLC): A JMTO study.
    Nakaga, M
    Teramukai, S
    Tada, H
    Furuse, K
    Tanaka, F
    Mio, T
    Mishima, M
    Wada, H
    Fukushima, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 667S - 667S
  • [33] Prognostic factors for the survival of surgically treated patients for non-small cell lung cancer
    Fernandes, OJCB
    Almgren, SO
    Thaning, L
    Filbey, D
    Helsing, M
    Karlsson, M
    Magnusson, A
    Souza, D
    ACTA ONCOLOGICA, 2003, 42 (04) : 338 - 341
  • [34] Prognostic Factors in Advanced Non-Small Cell Lung Cancer Patients Treated with Immunotherapy
    Rocco, Danilo
    Della Gravara, Luigi
    Ragone, Angela
    Sapio, Luigi
    Naviglio, Silvio
    Gridelli, Cesare
    CANCERS, 2023, 15 (19)
  • [35] Outcomes of Nivolumab in Elderly Patients (pts) with Non-Small Cell Lung Cancer (NSCLC)
    Bagley, Stephen
    Kothari, Shawn
    Aggarwal, Charu
    Bauml, Joshua
    Alley, Evan
    Evans, Tracey
    Kosteva, John
    Ciunci, Christine
    Thompson, Jeffrey
    Stonehouse-Lee, Susan
    Sherry, Victoria
    Gilbert, Elizabeth
    Eaby-Sandy, Beth
    Mutale, Faith
    Dilullo, Gloria
    Cohen, Roger
    Vachani, Anil
    Langer, Corey
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1289 - S1289
  • [36] A retrospective analysis of non-small cell lung cancer patients treated with nivolumab
    Akagi, Kazumasa
    Honda, Noritaka
    Umeyama, Yasuhiro
    Ogawara, Daiki
    Ikeda, Takaya
    Yamaguchi, Hiroyuki
    Kitazaki, Takeshi
    Nakatomi, Katsumi
    Fukuda, Minoru
    Mukae, Hiroshi
    ANNALS OF ONCOLOGY, 2017, 28
  • [37] Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy
    Branislav Jeremic
    Biljana Milicic
    Aleksandar Dagovic
    Jasna Aleksandrovic
    Nebojsa Nikolic
    Journal of Cancer Research and Clinical Oncology, 2003, 129 : 114 - 122
  • [38] Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy
    Jeremic, B
    Milicic, B
    Dagovic, A
    Aleksandrovic, J
    Nikolic, N
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2003, 129 (02) : 114 - 122
  • [39] The immune metabolic prognostic index discloses the presence of radiological progression in patients with non-small cell lung cancer (NSCLC) treated with Nivolumab
    Lanfranchi, F.
    Bauckneht, M.
    Genova, C.
    Rossi, G.
    Rijavec, E.
    Dal Bello, M. G.
    Ferrarazzo, G.
    Tagliamento, M.
    Delucchi, C.
    Donegani, M. I.
    Biello, F.
    Chiola, S.
    Zullo, L.
    Raffa, S.
    Cittadini, G.
    Marini, C.
    Sambuceti, G.
    Grossi, F.
    Morbelli, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S80 - S80
  • [40] Incidence of Nivolumab-Induced Pneumonitis and Interstitial Lung Disease (ILD) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Combined Analysis of Four Phase III Randomized Controlled Trials
    Kyaw, P. P.
    Ball, S.
    Zaw, M. H.
    Sultan, A.
    Mogollon-Duffo, F.
    White, P.
    Song, M.
    Thein, K. Z.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
12345